Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay

  • J Med Chem. 2025 Sep 11;68(17):18670-18683. doi: 10.1021/acs.jmedchem.5c01820.
Erdong Li  1 ,  Xiuqi Hu  1 ,  Lvbin Hu  1 ,  Yingping Li  2 ,  Jinglong Zhao  1 ,  Junjie Wang  1 ,  Yi Mou  2 ,  Zhengyu Jiang  1
Affiliations
  • 1. Jiang Su Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • 2. School of Pharmacy, Taizhou University, Taizhou 225300, China.
PMID: 40851258 DOI: 10.1021/acs.jmedchem.5c01820
Abstract

Casitas B-lineage lymphoma-b (Cbl-b), a pivotal negative regulator of TCR signaling, is highly expressed in immune cells. Its inhibition potentiates immune-mediated antitumor effects. Herein, we constructed a potent fluorescent tracer, Tracer 2, based on the Cbl-b peptide inhibitor Pep 1. Utilizing this tracer, we established a fluorescence polarization (FP) assay with enhanced sensitivity, discriminative capacity, and precision for the activity evaluation and high-throughput screening of orthosteric Cbl-b Src homology 2 (SH2) domain inhibitors. Leveraging this FP assay, we derived a potent phosphorylated peptidomimetic Cbl-b inhibitor, Pep 19, which significantly enhanced TCR signaling and promoted IL-2 secretion in Jurkat cells. Furthermore, in vivo studies demonstrated that Pep 19 exhibited robust immune-mediated antitumor effects in the CT26 syngeneic mouse model. This study not only established a validated FP-based screening platform but also identified Pep 19 as a lead compound for developing orthosteric Cbl-b SH2 domain small-molecule inhibitors for Cancer Immunotherapy.

Products